SUBSCRIBE
SUBSCRIBE
News   Drug Development

Study Shows Teva Pharmaceutical Industries Limited’s Laquinimod Slows MS

June 20, 2008 | 
1 min read

LONDON, June 20 (Reuters) - Teva Pharmaceutical Industries’ multiple sclerosis pill laquinimod appears to slow the disease and is well-tolerated by people with the relapsing form of the incurable condition, researchers said on Friday.

Clinical research Phase II Europe
MORE ON THIS TOPIC
IV infusion set on light blue background, top view. Space for text
Pipeline
BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data
April 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Brain , concept idea art of thinking, surreal portrait painting, conceptual artwork, 3d illustration
Neurodegenerative disease
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier
April 2, 2025
 · 
5 min read
 · 
Dan Samorodnitsky
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Climb up, hand help businessman build ladder
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
March 31, 2025
 · 
4 min read
 · 
Annalee Armstrong